KOAG Receives FDA Clearance for Vascette® HP Hemostatic Pad for Vascular Closure

MINNEAPOLIS, Aug. 22, 2022 /PRNewswire/ -- KOAG LLC, a Minneapolis-based medical device firm engaged in the design of innovative, topical vascular closure systems, announced today it received FDA clearance for its Vascette® HP device.

Vascette® is a unique, topical closure pad incorporating a proprietary, plant-derived hemostatic foam. The Vascette® patent-pending technology supports rapid hemostasis (blood stoppage) after cardiac catheterization without direct compression over the arterial puncture site (arteriotomy).

KOAG will exhibit the Vascette® HP at the Association for Vascular Access (AVA) congress in Minneapolis, September 30-Oct 2.

KOAG LLC is a privately held medical device organization headquartered in suburban Minneapolis, MN.

View original content:https://www.prnewswire.com/news-releases/koag-receives-fda-clearance-for-vascette-hp-hemostatic-pad-for-vascular-closure-301610164.html

SOURCE KOAG LLC

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

You just read:

KOAG Receives FDA Clearance for Vascette® HP Hemostatic Pad for Vascular Closure

Distribution channels: Banking, Finance & Investment Industry

EIN Presswire's priority is author transparency. We do our best to weed out false and misleading content. The content above is the sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above.